This study examines who is using GLP-1 agonists (Ozempic, Wegovy, Mounjaro) and their experiences, particularly regarding physical and mental health outcomes, side effects, and associations with disordered eating. Through surveys and interviews with users aged 18+, the research aims to identify the benefits and harms of these medications and provide insights into their real-world effects on health and wellbeing.
Aims
This international study seeks deeper insights into the experiences of people using Glucagon-Like Peptide (GLP-1) agonists such as Ozempic, Wegovy and Mounjaro. It aims to identify the potential benefits and harms of these medications on the physical and mental health of adults with and without a history of disordered eating or eating disorders.
Background
There has been substantial public interest in Ozempic, Wegovy, Mounjaro and similar drugs. At present, we don’t know much about who is using these medications. This study examines people’s experiences of GLP-1 agonists – the benefits, side effects, impacts on mental and physical health and lifestyle – to better understand the association with disordered eating
Subscribe to our newsletter!
© 2026 InsideOut
InsideOut acknowledges the tradition of custodianship and law of the Country on which the University of Sydney and Charles Perkins Centre campus stands. We pay our respects to those who have cared and continue to care for Country. We are committed to diversifying research and eliminating inequities and discrimination in healthcare. We welcome all people regardless of age, gender, race, size, sexuality, language, socioeconomic status, location or ability.